FDA clears 1st treatment for pancreatic cancer in 30 years, approving Optune Pax to improve survival with chemotherapy.

The FDA has approved a first-of-its-kind portable, noninvasive device that delivers alternating electrical fields for the treatment of locally advanced pancreatic cancer.Optune Pax (Novocure) releases ...

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...

Novocure (NASDAQ:NVCR) surged as much as 34% in premarket trading on Thursday after securing U.S. regulatory approval for its wearable therapy designed to treat pancreatic cancer. The U.S. Food and ...

A newly published scientific paper titled "Gene Expression Patterns in Lung Adenocarcinoma Cells in Response to Changes in Deuterium Concentration" (Csonka, G.I.; Papp, A.; Somlyai, I.; Somlyai, G.

The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a ...